Table 4.
Maintenance of Castration Levels of Testosterone
| Duration of | % T > 50 | ||
|---|---|---|---|
| GnRH Agonist | Patients, n | Study (wks) | ng/dL |
| Leuprolide acetate for | |||
| depot suspension | |||
| 7.5 mg | 56 | 24 | 9% |
| 22.5 mg | 92 | 24 | 3% |
| 30 mg | 49 | 48 | 8 % |
| Goserelin acetate implant | |||
| 3.6 mg | 160 | 48 | 9% |
| Triptorelin pamoate | |||
| 3.75 mg | 140 | 36 | 3% |
| 11.25 mg | 174 | 36 | 4/0% |
| Leuprolide acetate for | |||
| injectable suspension | |||
| 7.5 mg | 117 | 28 | 0% |
| 22.5 mg | 117 | 28 | 1% |
| 30 mg | 90 | 28 | 3% |
| Leuprolide acetate implant | |||
| 65 mg | 80 | 52 | 0% |
| Histrelin acetate implant | |||
| 50 mg | - | 52 | 3% |
GnRH, gonadotropin-releasing hormone; T, testosterone.